ACI Global Corporation Stock

ACI Global Corp., formerly Par Advance Technologies Corp., a clinical-stage biopharmaceutical company engaged in the development of natural and novel peptides for the treatment or prevention of infections due to multi-drug resistant bacteria and fungi. The Company's drug candidates are proprietary synthetic and natural peptides (small proteins). Antecedents for these compounds occur in nature as part of the immune system of animals, insects and plants. Generally, the peptides bind to and kill harmful microorganisms and cancer cells. P113D, the Company's product candidate for cystic fibrosis, has been awarded Orphan Drug designation by the United States Food and Drug Administration (FDA). Demegen is also developing a novel, synthetic antimicrobial peptide in a rinse formulation for the treatment and prevention of oral candidiasis. The Company's peptide technology can also be used to prevent serious damage to crops caused by fungal and bacterial diseases.